Bioventus (BVS) Stock Forecast & Price Target

Bioventus is supported by a streamlined portfolio of core franchises and emerging growth drivers, with management confident in HA injections, bone graft substitutes, and fracture care while also prioritizing PNS, PRP, ultrasonics, and international expansion. The company’s fundamentals have improved materially, as adjusted EBITDA margins expanded from low teens in 2022 to over 20% in 2025, free cash flow rose to over $72 million in 2025 from less than $38 million in 2024, and organic revenue growth reached +7.5% in FY25. Even after the CMS Bone Growth Stimulator pricing cut, the business maintained guidance of $600 million to $610 million in revenue and $84 million to $89 million in cash flow from operations, reinforcing confidence in cash generation, debt reduction, and long-term upside from incremental investment.

Bioventus is pressured by a structurally difficult operating backdrop, with large and well-capitalized competitors in spinal fusion and adjacent musculoskeletal markets limiting its ability to gain share while pricing and reimbursement remain fragile. Its products depend heavily on reimbursement, and the CMS fee schedule update effective as of May 18, 2026 should reduce U.S. bone growth stimulation revenue by about 10% in traditional Medicare, hitting more than half of the roughly $75 million U.S. bone growth stimulation business and creating an estimated $2-3 million FY/26 top-line headwind. In addition, costly FDA and global regulatory approvals, intense competition for sales talent and distributors, and acquisition-related integration and dilution risk all threaten margins and execution.